Clinical trial · Observational
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China
NCT06452329CI-TRIAL-00098361completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastroesophageal Junction Cancer | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Participants who received first-line nivolumab therapy for advanced GC/GEJC
- interventionNames
- Drug: Nivolumab
Primary outcomes (1)
- measure
- Time to progression (TTP)
- timeFrame
- Up to 68 months
Secondary outcomes (5)
- measure
- Objective response rate (ORR)
- timeFrame
- Up to 68 months
- measure
- Duration of response (DOR)
- timeFrame
- Up to 68 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants aged ≥ 18 years at date of first administration of nivolumab * Confirmed diagnosis of unresectable advanced or metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (histologically or cytologically) * Participants newly received nivolumab as first-line (1L) treatment between 15 June 2018 and 30 June 2023 * Participants with at least one tumor assessment after index date except for death or discontinuation due to Adverse Events Exclusion Criteria: * Participants with primary malignancies other than unresectable advanced or metastatic GC/GEJC * Participants who participate in an interventional clinical trial in or before 1L nivolumab treatment for advanced/metastatic GC/GEJC * Participants with known HER2 status positive * Participants who investigator deems inappropriate for inclusion, for example clinical data was incomplete
References
Publications (0)
Data not yet available
No reference posted for this study.